Eculizumab in the Management of Catastrophic Antiphospholipid Syndrome with Multiorgan Involvement: A Case Report
May 2025
in “
The Journal of Rheumatology
”
Studysummary In this case report, researchers detailed the clinical management and positive outcome of a 62-year-old woman with catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus, highlighting the potential effectiveness of Eculizumab in achieving disease remission and maintaining stability over 18 months.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This case report discusses the management of a 62-year-old female patient with catastrophic antiphospholipid syndrome (CAPS) secondary to systemic lupus erythematosus, presenting with renal and cardiopulmonary involvement. The patient was treated with a combination of hydroxychloroquine, corticosteroids, immunoglobulin therapy, mycophenolate, rituximab, and anticoagulation, alongside Eculizumab, a C5-blocking monoclonal antibody. Eculizumab was administered initially but was interrupted due to bacteremia. Despite this, the patient showed significant clinical improvement and normalization of laboratory values over 18 months without reintroducing Eculizumab. The report highlights the importance of early diagnosis and treatment in CAPS to prevent irreversible organ damage, suggesting that Eculizumab can be an effective part of the treatment regimen.
